Overview

Minagene’s testing utilizes targeted next-generation sequencing and immunohistochemistry to detect key driver mutations, fusions and immune biomarkers in lung adenocarcinoma, squamous cell carcinoma and small cell lung cancer specimens.

Methodology

DNA and RNA isolated from formalin-fixed paraffin-embedded biopsy/resection samples undergo hybrid capture-based enrichment of over 300 lung cancer-associated genes and loci. Simultaneous protein analysis assesses PD-L1 expression levels.

Key Highlights of Minagene’s Molecular Testing for Lung Cancer

-Identifies EGFR, ALK, ROS1, BRAF, KRAS mutations for targeted therapy

-Detects rare MET, RET, HER2 alterations with matched drugs

-Determines tumor mutation burden and microsatellite instability status

-Assesses PD-L1 to predict response to immune checkpoint inhibitors

-Guides clinical trial enrollment and combinatorial treatment strategies

By applying an integrated genomic and protein-based approach, physicians can select optimal first-line and subsequent lines of targeted and immune therapies tailored to each patient’s molecular profile.

Molecular testing should be ordered on all newly diagnosed lung cancers or at progression to optimize precision treatment planning based on actionable genomic alterations.